Andrew Chapel, DO
Cardiovascular Disease · Glendale, AZNPI 1619406352
Payments from drug & device makers
Across 171 payments — averaging $49.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$979
- Boston Scientific$815
- Edwards Lifesciences$755
- Novartis$669
- Johnson & Johnson$667
- Amgen$637
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,12596%
- Education$3444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $979 |
| Boston Scientific | 8 | $815 |
| Edwards Lifesciences | 8 | $755 |
| Novartis | 33 | $669 |
| Johnson & Johnson | 8 | $667 |
| Amgen | 39 | $637 |
| Medtronic | 4 | $629 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $626 |
| W. L. Gore & Associates, Inc. | 2 | $308 |
| Pfizer | 9 | $256 |
| Amarin Pharma, Inc. | 2 | $226 |
| Cleerly, Inc. | 1 | $180 |
| Philips North America LLC | 3 | $173 |
| Cardiovascular Systems Inc. | 1 | $172 |
| E.r. Squibb & Sons, L.L.C. | 7 | $143 |
| Endologix LLC | 1 | $143 |
| Heartflow, Inc. | 1 | $140 |
| Impulse Dynamics (USA) Inc. | 1 | $135 |
| Shockwave Medical, Inc | 1 | $131 |
| Cook Medical LLC | 1 | $109 |
| Penumbra, Inc. | 1 | $74 |
| Actelion Pharmaceuticals US, Inc. | 2 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $50 |
| Veryan Medical Incorporated | 1 | $48 |
| Angiodynamics, Inc. | 1 | $48 |
| Merck | 2 | $48 |
| Boehringer Ingelheim | 2 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Endotronix, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Cvrx, Inc. | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$510
- XARELTO$466
- CARDIOMEMS$362
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$308
- LifeVest$295
- OPTIMIZER$269
- Vascepa$226
- Ensite Cardiac Mapping System$208
- COREVALVE EVOLUT R$190
- Cleerly Ischemia$180
- Cleerly Labs$180
- Micra$173
- Diamondback Coronary$172
- WATCHMAN FLX$172
- WATCHMAN Access System$147
- Edwards SAPIEN 3 Transcatheter Heart Valve$144
- Ovation iX Iliac Stent Graft$143
- Endurant$142
- SYNERGY$141
- FFRct$140
How this compares
$8,469 in reported general payments places this provider in the 70th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $106,409 |
| Repatha SureclickEvolocumab | 50 | $37,408 |
| JardianceEmpagliflozin | 25 | $35,629 |
| EntrestoSacubitril/Valsartan | 24 | $29,561 |
| XareltoRivaroxaban | 22 | $19,933 |
| Repatha SyringeEvolocumab | 12 | $9,554 |
| Atorvastatin Calcium | 336 | $3,097 |
| Ranolazine ErRanolazine | 12 | $2,588 |
| Rosuvastatin Calcium | 195 | $2,558 |
| Metoprolol Succinate | 156 | $2,539 |
| Ezetimibe | 55 | $1,313 |
| Torsemide | 84 | $1,285 |
| Amiodarone Hcl | 12 | $1,277 |
| Losartan Potassium | 138 | $1,113 |
| Carvedilol | 96 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $256 | $106,409103 claims |
| Boehringer IngelheimJardiance | $47 | $35,62925 claims |
| NovartisEntresto | $669 | $29,56124 claims |
| Johnson & JohnsonXarelto | $667 | $19,93322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Glendale
- Fred CucherGlendale$82K
- David RizikScottsdale$2.1M
- Rodrigo ChanMesa$2M
- Ashish GuptaPhoenix$1.2M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Gregory KoshkarianTucson$608K
- Andrew KaplanMesa$455K
- Charles JostMesa$374K
- Steven MottlTucson$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.